RxDoctor Payments DataLook up a doctor →

Susan Wilson

Oncology · Marmora, NJNPI 1396757811

Payments from drug & device makers

$10,430in general payments, 2019–2025

Across 461 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • AstraZeneca$637
  • Incyte Corporation$622
  • Gilead$503
  • Merck$489
  • E.r. Squibb & Sons, L.L.C.$440
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$9,23489%
  • Education$3633%
  • Other$8338%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis18$1,021
AstraZeneca(2 entities)35$637
Incyte Corporation17$622
Gilead(2 entities)25$503
Merck30$489
E.r. Squibb & Sons, L.L.C.22$440
Eisai Inc.25$414
Astellas Pharma US Inc16$384
Daiichi Sankyo Inc.19$373
Takeda Pharmaceuticals U.S.A., Inc.12$334
EMD Serono, Inc.2$291
Bristol Myers Squibb19$290
Bayer15$289
Johnson & Johnson(2 entities)13$276
Pfizer15$268
GSK10$255
Sobi, Inc8$236
Seagen Inc.8$216
Amgen11$209
Stemline Therapeutics Inc.3$163
Lilly USA, LLC9$151
Boston Scientific1$145
Myriad Genetic Laboratories, Inc.2$144
Servier Pharmaceuticals LLC6$115
Tempus AI, Inc5$114
Genentech USA, Inc.7$113
Acrotech Biopharma Inc.5$112
AVEO Pharmaceuticals, Inc.2$109
Pharmacosmos Therapeutics Inc.7$107
Genmab U.S., Inc.5$99
Karyopharm Therapeutics Inc.6$95
Puma Biotechnology, Inc.6$94
Sanofi5$89
Coherus Oncology, Inc.2$88
Pharmacyclics LLC, An Abbvie Company6$85
Mirati Therapeutics, Inc.4$81
Array Biopharma Inc5$75
Tersera Therapeutics LLC4$74
AbbVie4$61
Adaptive Biotechnologies Corporation3$57
Taiho Oncology, Inc.4$56
Regeneron Healthcare Solutions, Inc.3$47
Spectrum Pharmaceuticals Inc.2$44
Boehringer Ingelheim3$42
Deciphera Pharmaceuticals Inc.2$36
Azurity Pharmaceuticals, Inc.2$35
Recordati_rare_diseases_inc.2$33
Kyowa Kirin, Inc.2$32
Springworks Therapeutics, Inc.2$31
Sumitomo Pharma America, Inc.2$31
Beigene USA, Inc.2$31
Morphosys, US Inc.2$29
CTI Biopharma Corp.1$28
ADC Therapeutics America, Inc.1$23
Beone Medicines USA, Inc.1$20
Helsinn Therapeutics (U.S.), Inc.1$20
Secura Bio, Inc.2$18
Pharmaessentia USA Corporation1$18
Ipsen Biopharmaceuticals, Inc1$18
EUSA Pharma (US) LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,430 in reported general payments places this provider in the 95th percentile of 23 oncology providers in New Jersey.

See all oncology providers in New Jersey

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban40$42,154
XareltoRivaroxaban25$25,952
Morphine Sulfate ErMorphine Sulfate12$354
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15$276
Letrozole12$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$268$42,15440 claims
Johnson & JohnsonXarelto$276$25,95225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 23 oncology providers in New Jersey.

Other oncology in Marmora

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →